Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: The present invention relates to TCP peptides for use in methods of treatment of S protein viruses. Notably, said TCP peptides are useful for treatment of inflammation associated with infection by S protein virus. The invention also provides methods for predicting the severity of infection by S protein virus.

Abstract: The present invention relates to compositions comprising: a) a thrombin derived peptide and, b) a non-ionic polymer capable of forming a hydrogel and c) an aqueous solution. The invention also provides compositions comprising: a) a thrombin derived peptide and, b) EDTA and c) an aqueous buffer. The invention also provides compositions comprising: a) a thrombin derived peptide in high concentration. A product comprising the compositions, as well as the compositions or the products for use in a method of treatment are also disclosed.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: IRF-7 inhibitors have been found to be useful in the treatment of infections, such as bacterial infections. Suitable inhibitors include siRNA molecules as well as small molecules. The inhibitors may be particularly useful in the treatment of bacterial kidney infection, and especially in the treatment of patients having a genetic susceptibility to acute pyelonephritis.

Abstract: IRF-7 inhibitors have been found to be useful in the treatment of infections, such as bacterial infections. Suitable inhibitors include siRNA molecules as well as small molecules. The inhibitors may be particularly useful in the treatment of bacterial kidney infection, and especially in the treatment of patients having a genetic susceptibility to acute pyelonephritis.